Biospace: Companies Bank on Psychedelics as Treatments for Mental Health Disorders

The coming years could see a massive shift in the U.S. government’s approach to regulating hallucinogenic drugs. Several biopharma companies are developing psychedelics-based treatments for various mental health conditions, and in 2017 the FDA granted breakthrough status to psychedelic-assisted therapies using both MDMA (ecstasy) for the treatment of post-traumatic stress disorder and psilocybin (the active ingredient in “magic” mushrooms) for patients with depression. Should the agency greenlight these products, they could become much easier for researchers, and possibly patients, to access.

Originally appearing here (Archived)